Intellia Therapeutics (NTLA) Other Accumulated Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Other Accumulated Expenses for 12 consecutive years, with $11.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 289.49% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $11.8 million (up 289.49% YoY), while the FY2025 annual figure was $17.4 million, down 34.12% from the prior year.
• Other Accumulated Expenses eased to $11.8 million in Q1 2026 per NTLA's latest filing, from $17.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $30.3 million in Q3 2022 and bottomed at $2.3 million in Q3 2024.
• Historically, Other Accumulated Expenses has averaged $12.9 million across 5 years, with a median of $5.7 million in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 1179.88% — and 2024, when it sank 90.5%.
• Intellia Therapeutics' Other Accumulated Expenses stood at $5.0 million in 2022, then soared by 452.98% to $27.4 million in 2023, then fell by 3.83% to $26.4 million in 2024, then plunged by 34.12% to $17.4 million in 2025, then slumped by 32.11% to $11.8 million in 2026.
• Business Quant data shows NTLA's Other Accumulated Expenses at $11.8 million in Q1 2026, $17.4 million in Q4 2025, and $5.6 million in Q3 2025.